Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


Targeted drugs score more wins

Posted 17 January 2019

Therapies targeting specific genetic mutations are more than twice as likely to receive regulatory approval, a new study claims. 

Three researchers working at the AbbVie Genomics Research Center in Chicago found drugs with "genetic support" had higher rates of approval compared to those which did not use genetic markers. 

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Biden and the MA agreement
'Global decisions' will influence ongoing negotiations
Special Report
PBAC March agenda
Every major and minor sub sorted by indication
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas